Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET

Company Participants

David Nakasone - Head of Investor Relations
Bobby Azamian - Chief Executive Officer and Chairman
Aziz Mottiwala - Chief Commercial Officer
Jeff Farrow - Chief Financial Officer and Chief Strategy Officer
Sesha Neervannan - Chief Operating Officer

Conference Call Participants

Eddie Hickman - Guggenheim Securities
Balaji - Barclays
Francois Brisebois - Oppenheimer
Jason Gerberry - Bank of America
Andrea Tan - Goldman Sachs
Corey Jubinville - Life Sci Capital

Operator

Good afternoon, and welcome to Tarsus's First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. Please go ahead.

David Nakasone

Thank you. Before we begin, I encourage everyone to go to the Investors Section of the Tarsus website to view the earnings release and related materials we will be discussing today.

Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman; Aziz Mottiwala, our Chief Commercial Officer; Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer; and joining us for the question-and-answer session Sesha Neervannan, our Chief Operating Officer.

I'd like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I would like to turn the call over to Bobby.

Bobby Azamian

Good afternoon, everyone and thank you for joining us. 2024 is off to a great start for Tarsus, and I'm excited to share our progress with you today. We continue to build and grow a new category with exceptional commercial performance and make strides to do it again with the advancement of our pipeline.

I'll start with XDEMVY, the first and only FDA-approved treatment for Demodex blepharitis, or DB for short, which is continuing on a tremendous pace and not just in terms of sales. We are establishing a new market, and I know we are only scratching the surface of what we can achieve with XDEMVY for DB patients and their doctors. In just the second full quarter of launch, we are seeing increased adoption amongst both existing and first-time prescribers, as well as increasing demand among patients.